Home Blog

0 0

Patent Number: 8,942,458

Grant date: December 31, 1969
Priority date: May 14, 1999
Estimated expiration date: May 14, 2019
Inventor(s): Takahashi; Toru (Tokyo, JP), Tsukii; Ken (Tokyo, JP), Xu; Jie (Tokyo, JP)
Assignee(s): Furukawa Electric Co., Ltd. (Tokyo, JP)
External link: USPTO website

Abstract:

A method for distinguishing and sorting cells characterized by comprising distinguishing and sorting a specific cell mass or a part of the cells in the cell mass with the use of transmitted light data reflecting the morphological characteristics of the cells such as size and shape optionally together with side-scattering light data reflecting the characteristics of the internal structure of the cells. The part of the cells in the specific cell mass as described above are at the G1 stage or at a part of the M stage in the cell cycle. A part of the cells at the G1 stage are referred to as the left bottom line in an analytical dispersion diagram of the cells wherein the abscissa indicates the transmitted light data, while a part of the cells at the M stage are referred to as the right bottom line in the analytical dispersion diagram of the cells wherein the abscissa indicates the transmitted light data.

0 0

Patent Number: 8,940,871

Grant date: December 31, 1969
Priority date: May 14, 1999
Estimated expiration date: May 14, 2019
Inventor(s): Wu; Anna M. (Sherman Oaks, CA), Reiter; Robert E. (Los Angeles, CA)
Assignee(s): The Regents of the University of California (Oakland, CA)
External link: USPTO website

Abstract:

The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and for cancer imaging.

0 0

Patent Number: 8,940,698

Grant date: December 31, 1969
Priority date: May 14, 1999
Estimated expiration date: May 14, 2019
Inventor(s): Malinin; Theodore I. (Key Biscayne, FL)
Assignee(s): Vivex Biomedical, Inc. (Marietta, GA)
External link: USPTO website

Abstract:

Cartilage materials such as cartilage fluff and a cartilage composition comprising a particulate material are disclosed. These are suitable for stimulating chondrogenesis and/or producing cartilage regeneration. Also disclosed are processes for their preparation. Methods for regenerating articular cartilage are also disclosed, which involve, for example, placing the cartilage fluff or cartilage composition into a cartilage defect.

0 0

Patent Number: 8,940,537

Grant date: December 31, 1969
Priority date: May 14, 1999
Estimated expiration date: May 14, 2019
Inventor(s): Reubinoff; Benjamin (Doar Na Haela, IL), Steiner; Debora (Modi’in, IL)
Assignee(s): Hadasit Medical Research Services & Development Limited (Jerusalem, IL)
External link: USPTO website

Abstract:

The present disclosure provides methods for maintaining and propagating undifferentiated pluripotent stem cells (SC) in suspension. The methods comprise culturing such SC in a non-adherent culture dish under conditions comprising a basic serum free medium and one or more of a basic medium, a serum replacement, an extra cellular matrix component and a factor supporting expansion of said SC. A specific and preferred culture condition comprise supplementing Neurobasal.TM. medium with KO serum replacement (KOSR). These conditions allowed for large scale and long term propagation of undifferentiated pluripotent SC. The culture system comprising suspended undifferentiated pluripotent SC were found to have many applications including in methods for directed as well as spontaneous differentiation of the SC into somatic cells. Also disclosed herein is a method of deriving SC, preferably human embryonic SC from human embryos via the formation of cell clusters.

0 0

Patent Number: 8,940,536

Grant date: December 31, 1969
Priority date: May 14, 1999
Estimated expiration date: May 14, 2019
Inventor(s): Jaenisch; Rudolf (Brookline, MA), Hochedlinger; Konrad (Cambridge, MA)
Assignee(s): Whitehead Institute for Biomedical Research (Cambridge, MA)
External link: USPTO website

Abstract:

The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.

0 0

Patent Number: 8,940,535

Grant date: December 31, 1969
Priority date: May 14, 1999
Estimated expiration date: May 14, 2019
Inventor(s): Trisler; G. David (Chevy Chase, MD), Bever, Jr.; Christopher T. (Glen Arm, MD), Goolsby; James E. (Baltimore, MD), Pessac; Bernard M. (Paris, FR)
Assignee(s): University of Maryland, Baltimore (Baltimore, MD) The United States of America as Represented by the Dept of Veterans Affairs (Washington, DC)
External link: USPTO website

Abstract:

Methods and compositions are provided for isolation of proliferating cells. In particular, the methods enrich stem cells in a mixture of stem cells and non-stem cells, and in some cases the non-stem cells may be differentiated cells. The methods exploit the non-adherent property of stem cells, as opposed to the adherent property of differentiating cells, by serially passaging the suspended cells in liquid media.

0 0

Patent Number: 8,940,533

Grant date: December 31, 1969
Priority date: May 14, 1999
Estimated expiration date: May 14, 2019
Inventor(s): Oshimura; Mitsuo (Tottori, JP), Kazuki; Yasuhiro (Tottori, JP), Takiguchi; Masato (Tottori, JP), Matsuoka; Takashi (Tottori, JP)
Assignee(s): National University Corporation Tottori University (Tottori, JP) Chromocenter Inc. (Tottori, JP)
External link: USPTO website

Abstract:

Disclosed is a mouse artificial chromosome vector, comprising: a natural centromere derived from a mouse chromosome; a mouse-chromosome-derived long-arm fragment formed by deleting a long-arm distal region at a mouse chromosome long-arm site proximal to the centromere; and a telomere sequence, wherein the vector is stably retained in a cell and/or tissue of a mammal. In addition, disclosed are cells or non-human animals comprising the vector, and use of the cells or non-human animals.

0 0

Patent Number: 8,940,500

Grant date: December 31, 1969
Priority date: May 14, 1999
Estimated expiration date: May 14, 2019
Inventor(s): Gostjeva; Elena V. (Winchester, MA), Thilly; William G. (Winchester, MA)
Assignee(s): Massachusetts Institute of Technology (Cambridge, MA)
External link: USPTO website

Abstract:

Methods are disclosed for the characterization of the stage of development or pathology of a tissue sample, and for identifying pluripotent metakaryotic stem cells, comprising detecting fluorescence of cells and syncytia in fixed samples treated with a non-fluorescent Schiff’s base reagent in the absence of extraneous or exogenously added fluorescent dyes.

0 0

Patent Number: 8,940,494

Grant date: December 31, 1969
Priority date: May 14, 1999
Estimated expiration date: May 14, 2019
Inventor(s): Prabhakarpandian; Balabhaskar (Madison, AL), Pant; Kapil (Huntsville, AL)
Assignee(s): CFD Research Corporation (Huntsville, AL)
External link: USPTO website

Abstract:

Methods of assaying the leukocyte adhesion cascade (LAC) and monitoring leukocyte rolling, adhesion, and/or migration can be implemented with an apparatus that includes an idealized microvascular network (IMN) of one or more interconnected idealized flow channels in fluid communication through a porous wall with a tissue space (e.g., idealized tissue space). The methods of assaying the LAC can be implemented with means for quantifying modulation of the leukocyte adhesion cascade. Methods of assaying the LAC can be implemented with the device and one or more active agents to monitor leukocyte rolling, adhesion, and/or migration in the presence of absence of the active agent. Migration can be through the idealized flow channels, through the porous wall, and/or into the tissue space.

0 0

Patent Number: 8,940,301

Grant date: December 31, 1969
Priority date: May 14, 1999
Estimated expiration date: May 14, 2019
Inventor(s): Wicha; Max S. (Ann Arbor, MI), Ginestier; Christophe (Marseille, FR)
Assignee(s): The Regents of The University of Michigan (Ann Arbor, MI)
External link: USPTO website

Abstract:

The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).